These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25413708)

  • 21. Qualitative pharmacology in a quantitative world: diminishing value in the drug discovery process.
    Williams M
    Curr Opin Pharmacol; 2011 Oct; 11(5):496-500. PubMed ID: 21531622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using label-free screening technology to improve efficiency in drug discovery.
    Halai R; Cooper MA
    Expert Opin Drug Discov; 2012 Feb; 7(2):123-31. PubMed ID: 22468914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [An introduction to QSP modeling for pharmacologists].
    Sayama H; Nagasaka Y; Tabata K
    Nihon Yakurigaku Zasshi; 2019; 154(3):143-150. PubMed ID: 31527365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.
    Janero DR
    Expert Opin Drug Discov; 2014 Aug; 9(8):847-58. PubMed ID: 24965547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mass spectrometry technology and its application in analysis of biological samples].
    Zhao LS; Li Q; Guo CW; Chen XH; Bi KS
    Yao Xue Xue Bao; 2012 Feb; 47(2):158-62. PubMed ID: 22512024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment.
    Campbell JL; Le Blanc JC
    Bioanalysis; 2011 Mar; 3(6):645-57. PubMed ID: 21417733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomics for bioactivity assessment of natural products.
    Yuliana ND; Khatib A; Choi YH; Verpoorte R
    Phytother Res; 2011 Feb; 25(2):157-69. PubMed ID: 20658470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technologies and strategies to characterize and quantitate metabolites in drug discovery and development.
    Ravindran S; Jadhav A; Surve P; Lonsane G; Honrao P; Nanda B
    Biomed Chromatogr; 2014 Nov; 28(11):1547-53. PubMed ID: 25175001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of target identity and biology: implications for drug discovery and development.
    Patel AC
    J Biomol Screen; 2013 Dec; 18(10):1164-85. PubMed ID: 24080260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical proteomics and its impact on the drug discovery process.
    Miao Q; Zhang CC; Kast J
    Expert Rev Proteomics; 2012 Jun; 9(3):281-91. PubMed ID: 22809207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolomics and its potential in drug development.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2013 Jan; 85(1):12-20. PubMed ID: 22935449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry for small molecule pharmaceutical product development: a review.
    Gillespie TA; Winger BE
    Mass Spectrom Rev; 2011; 30(3):479-90. PubMed ID: 21500245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development.
    Dingemanse J; Krause A
    Eur J Pharm Sci; 2017 Nov; 109S():S53-S58. PubMed ID: 28535992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies.
    Ramesh M; Trivedi RK; Srinivas NR
    Bioanalysis; 2009 Jun; 1(3):619-28. PubMed ID: 21083157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward a new age of cellular pharmacokinetics in drug discovery.
    Zhou F; Zhang J; Li P; Niu F; Wu X; Wang G; Roberts MS
    Drug Metab Rev; 2011 Aug; 43(3):335-45. PubMed ID: 21395404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal models of human disease: challenges in enabling translation.
    McGonigle P; Ruggeri B
    Biochem Pharmacol; 2014 Jan; 87(1):162-71. PubMed ID: 23954708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.